These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8001030)

  • 1. Histamine in immunotherapy of advanced melanoma: a pilot study.
    Hellstrand K; Naredi P; Lindner P; Lundholm K; Rudenstam CM; Hermodsson S; Asztély M; Hafström L
    Cancer Immunol Immunother; 1994 Dec; 39(6):416-9. PubMed ID: 8001030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
    Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
    Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
    Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
    Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P
    Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
    Donskov F; von der Maase H; Henriksson R; Stiemer U; Wersäll P; Nellemann H; Hellstrand K; Engman K; Naredi P
    Ann Oncol; 2002 Mar; 13(3):441-9. PubMed ID: 11996477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    Schmidt H; Larsen S; Bastholt L; Fode K; Rytter C; Von Der Maase H
    Ann Oncol; 2002 Dec; 13(12):1919-24. PubMed ID: 12453861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polychemotherapy in advanced malignant melanoma.
    Foppoli M; Citterio G; Polastri D; Guerrieri R
    Tumori; 1995; 81(2):102-6. PubMed ID: 7778212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
    Atzpodien J; Neuber K; Kamanabrou D; Fluck M; Bröcker EB; Neumann C; Rünger TM; Schuler G; von den Driesch P; Müller I; Paul E; Patzelt T; Reitz M
    Br J Cancer; 2002 Jan; 86(2):179-84. PubMed ID: 11870502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
    Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
    Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
    Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
    Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.